Press Releases

In This Section

Breadcrumb

Home // Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Sept. 15, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of two separate
View HTML
Toggle Summary Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors
VANCOUVER, British Columbia , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Suzanne Bruhn , Ph.D.
View HTML
Toggle Summary Novelion Therapeutics Reports Second Quarter 2017 Financial Results
MYALEPT® Total Net Revenues Increase 28% Over Prior Quarter, Excluding One-Time Adjustments Global Expansion Plans for Metreleptin Opportunity Underway Company Updates Guidance for FY 2017 Total Net Revenues Conference call to be held today at 8:30 a.m. ET VANCOUVER , Aug.
View HTML
Toggle Summary Novelion Therapeutics Appoints Mark DiPaolo to Board of Directors
VANCOUVER, British Columbia , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark DiPaolo to its board of directors,
View HTML
Toggle Summary Novelion Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
Conference call and Webcast Scheduled for 8:30am ET
View HTML
Toggle Summary Novelion Therapeutics Added to the Russell 3000® & Russell Microcap® Indexes
VANCOUVER, British Columbia , June 26, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that it has been added to the Russell 3000® and Russell
View HTML
Toggle Summary Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , June 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of data by researchers
View HTML
Toggle Summary Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , June 01, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of John J.
View HTML
Toggle Summary Novelion Therapeutics Reports First Quarter 2017 Financial Results
Global Expansion Plans for Metreleptin Opportunity to be Announced this Summer   Defined Clinical Development Plan for Zuretinol Following Positive FDA Meeting Company Reiterates FY 2017 Total Net Revenues Guidance Between $155 and $165 million Conference call to be held today at 8:30 a.m.
View HTML
Toggle Summary Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , May 05, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of data by
View HTML